NCT07031154View on ClinicalTrials.gov

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions
Non-Small Cell Lung CancerAdebrelimabApatinib
Interventions
DRUG

Adebrelimab

Adebrelimab 1200mg, iv, D1，Q3W

DRUG

Apatinib

Apatinib 250mg，P.O，qd，Q3W

Trial Locations (1)

Unknown

First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER